Free FDA Online Program about FDA's Role in Public Health - Drug Efficacy, Safety, Quality, and Beyond

Free FDA Online Program about FDA's Role in Public Health

The FDA is offering a free online class "FDA's Role in Public Health: Drug Efficacy, Safety, Quality, and Beyond" available at http://fdadrugregulations.e-paga.com/

Here is more information from their website about it:

This activity is supported by the US Food and Drug Administration (FDA) through a contract from the Department of Health and Human Services, and FDA's privacy policies apply while you are on this site.
Continuing Education Credits (CE) Released: 2/25/2016; Valid for credit through: 2/24/2019

Credits Available:

Physicians – 1.5 AMA PRA Category 1 Credit(s)™
Nurses – 1.5 ANCC Contact Hours
Pharmacists – 1.5 ACPE Contact Hours
Nurse Practitioners – 1.5 AANP Contact Hours
Physician Assistants – 1.5 hours of Category I Credit

Certificates of Completion:

For users wishing to have confirmation that they have completed this course, they may choose to receive a Certificate of Completion which comes with no CE credits.

Target Audience:

The target audience for this course is healthcare professionals, including physicians, physician assistants, nurses, nurse practitioners, and pharmacists. The course can be taken for informational purposes or for Continuing Education (CE) credit.

Description:

This activity explains how U.S. public health policy has influenced and shaped the Food and Drug Administration (FDA) protections that Americans have come to expect, provides an overview of FDA’s Center for Drug Evaluation and Research, or CDER’s, role in the regulation of new drug development, marketed drugs, quality testing, and post-market surveillance, and identifies new directions for the human drug regulatory process in the United States.

Free FDA Online Program about FDA's Role in Public Health

Learning Objectives: Upon completion of this activity, participants should be able to:

1. Describe and explain the drug development and review process in the United States for new drugs, generics, over-the-counter (OTC) drugs, and biosimilars
2. Outline CDER’s role in post-marketing safety surveillance for medical products
3. Identify ways CDER disseminates safety information about medical products to both health care professionals and their
4. Describe CDER initiatives and commitments for the protection of public health
5. Describe the new drug development and review process

Learn more about Careers in Clinical Research

Subscribe to our Clinical Research Newsletter!

* indicates required

Email Address *

First Name

Last Name